Clinical trial
VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With…
NCT00111319 · Millennium Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00111319 |
|---|---|
| Title | VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma |
| Official title | An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects With Previously Untreated Multiple Myeloma |
| Lead sponsor | Millennium Pharmaceuticals, Inc., Industry |
| Collaborators | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | bortezomib |
| Start date | Dec 1, 2004 |
| Primary completion | Jul 1, 2007 |
| First posted | May 20, 2005 |
| Last update posted | Mar 26, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: